Heron Therapeutics (HRTX) Receivables - Other (2020 - 2025)
Heron Therapeutics (HRTX) has disclosed Receivables - Other for 6 consecutive years, with $344000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 30.8% year-over-year to $344000.0, compared with a TTM value of $344000.0 through Dec 2025, up 30.8%, and an annual FY2025 reading of $344000.0, up 30.8% over the prior year.
- Receivables - Other was $344000.0 for Q4 2025 at Heron Therapeutics, up from $263000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $6.2 million in Q4 2022 and bottomed at $21000.0 in Q4 2023.
- Average Receivables - Other over 5 years is $1.4 million, with a median of $263000.0 recorded in 2024.
- The sharpest move saw Receivables - Other skyrocketed 2429.39% in 2022, then crashed 99.66% in 2023.
- Year by year, Receivables - Other stood at $245000.0 in 2021, then surged by 2429.39% to $6.2 million in 2022, then plummeted by 99.66% to $21000.0 in 2023, then soared by 1152.38% to $263000.0 in 2024, then skyrocketed by 30.8% to $344000.0 in 2025.
- Business Quant data shows Receivables - Other for HRTX at $344000.0 in Q4 2025, $263000.0 in Q4 2024, and $21000.0 in Q4 2023.